Načítá se...
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Small cell lung cancer (SCLC), which accounts for 10%–15% of lung cancer cases, is an aggressive disease characterized by rapid growth and early widespread metastasis. Although up to 80% of patients respond to first-line chemotherapy, most eventually relapse, and there are no approved agents beyond...
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4978554/ https://ncbi.nlm.nih.gov/pubmed/27354668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0523 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|